Biocon’s arm enters into strategic collaboration agreement with Civica

07 Mar 2025 Evaluate

Biocon’s subsidiary -- Biocon Biologics (BBL) and Civica, Inc. (Civica), a not-for-profit generic drug and pharmaceutical company founded in 2018 to address and resolve life-saving drug shortages and affordability, have entered into a strategic collaboration agreement to expand access and affordability of Insulin Aspart in the United States. 

Under the terms of the agreement, Biocon Biologics will supply Insulin Aspart drug substance to Civica, Inc., who will use the drug substance to produce Insulin Aspart drug product, a rapid-acting insulin analog, at its manufacturing facility in Petersburg, Virginia. Civica will commercialize the medicine for patients in the United States, after completion of development work and clinical trials. No technology transfer is involved in the agreement. 

This collaboration is in addition to Biocon Biologics’ own Insulin Aspart Drug Product for the United States which is currently under U.S. Food and Drug Administration (FDA) review. There are 38.4 million people with diabetes in the United States, around 11.6 percent of the total population, with nearly a quarter being undiagnosed. An additional 97.6 million Americans have been identified as prediabetic. 

Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.


Biocon Share Price

376.30 -1.25 (-0.33%)
19-Jan-2026 11:41 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1678.15
Dr. Reddys Lab 1169.85
Cipla 1381.25
Zydus Lifesciences 865.55
Lupin 2175.95
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×